International Research in Chinese Medicine

Objective To evaluate the value of sequential combination therapy of Kangfu anti-inflammatory suppository and azithromycin for acute pelvic inflammatory disease. Methods From December 2023 to December 2024, 80 cases of acute pelvic inflammatory disease were selected from the admitted patients and randomly divided into two groups using a random number table. The control group received conventional treatment with azithromycin, while the observation group received sequential treatment with Kangfu anti-inflammatory suppositories in addition to the control group. Through systematic observation and data analysis, a comprehensive comparison was made between the two groups in terms of clinical treatment efficacy, duration of symptom relief, and serum inflammatory cytokine levels. Results The total effective rate of the observation group was higher than that of the control group, and the disappearance time of abdominal pain, fever, abnormal vaginal discharge, and pelvic mass was shorter than that of the control group. The levels of CRP, IL-6, and TNF - α were lower than those of the control group (p<0.05). Conclusion The sequential combination therapy of Kangfu anti-inflammatory suppository and azithromycin can significantly improve the treatment effect of acute pelvic inflammatory disease, effectively reduce the inflammatory response in the body, and has good safety, which is worthy of further promotion.

Acute pelvic inflammatory disease; Kangfu anti-inflammatory suppository; Azithromycin; Sequential combination therapy